Acquired Haemophilia Therapeutics Market size is expected to grow at 4.9% throughout the forecast period, reaching nearly US$ 17.77 Bn. by 2029. Acquired Haemophilia is a rare genetic disorder, which is characterized by bleeding that occurs in patients with a negative personal or family history for haemorrhages. Autoimmune disorders occur when the body’s immune system mistakenly attacks healthy cells or tissue. In Acquired Haemophilia (AH), the body produces antibodies that attack clotting factors. Clotting factors are specialized proteins required for the blood to clot normally.To know about the Research Methodology :- Request Free Sample Report The treatment of Haemophilia comprises two approaches- To control bleeding episodes and other is to reduce inhibitor titer against clotting factor VIII in blood serum. To counter these blood complications, physicians prefer therapeutic drugs such as Desmopressin and Obizur. Increasing geriatric population and exceptional drug pharmacodynamic and pharmacokinetic profile shown by the immunomodulatory therapy are key drivers for the AH therapeutics market growth. Promising results showed up by the immunomodulatory agents in phase III clinical trials, will increase its demand as the first-line drug therapy to reduce the inhibitors pertaining to clotting factor VIII in the blood serum. However, the high costs associated with the bypassing agents used to control bleeding episodes may hamper market growth. The report covers the detailed analysis of global Acquired Haemophilia Therapeutics Market with the classifications of the market based on therapy type, Distribution channels, and region. Analysis of past market dynamics from 2017 to 2022 is given in the report, which will help readers to benchmark the past trends with current market scenarios with the key players contribution in it. The report has profiled fourteen key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analysing the market and estimation the size of the same. The growing healthcare infrastructure in each region is different and focus is given on availability of advanced technology and new techniques. Report has come up with recommendations for future hot spot in APAC region. New research findings, funding policies for projects and its impact on AH Therapeutics market are covered ion the report.
Acquired Haemophilia Therapeutics Market Segment Analysis
The advanced therapy segment is expected to grow because of advanced tests which are performed often. The first step in AH is to control bleeding, which is done by injecting blood clotting factors. The bypassing agents for this include Activated Factor VII (NovoSevenRT) or Activated Prothrombin Complex Concentrates (aPCC). Hence, as the first line of treatment, these therapeutics are increasing market growth. The market for advanced therapies is expected to grow by $ xx Mn in the forecast period.Acquired Haemophilia Therapeutics Market Regional Insights
North America is currently dominating the Acquired Haemophilia Therapeutics Market. The factors responsible for market growth are increasing public health awareness regarding autoimmune diseases, which is leading to early diagnosis and treatment. Affordable reimbursement policies for treating acquired haemophilia is expected to strengthen the market growth in this region. Europe represents a market share of 31%, the reason being the presence of key companies such as Baxter Healthcare Corporation, GlaxoSmithKline, Shire Plc and Novo Nordisk in this region. Asia Pacific holds 16% of market share and is expected to grow by $ xx Mn during the forecast period. The rising prevalence of acquired haemophilia and developing healthcare infrastructure are contributing to market growth.Acquired Haemophilia Therapeutics Market Scope:Inquire before buying
Acquired Haemophilia Therapeutics Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2017 to 2022 Market Size in 2022: US $ 12.71 Bn. Forecast Period 2023 to 2029 CAGR: 4.9% Market Size in 2029: US $ 17.77 Bn. Segments Covered: by Therapy Type • Traditional Therapy • Advanced Therapy by Distribution Channels • Hospital Pharmacies • Retail Pharmacies • Online Pharmacies Acquired Haemophilia Therapeutics Market, by Region
• North America (United States, Canada and Mexico) • Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) • Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) • Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) • South America (Brazil, Argentina Rest of South America)Acquired Haemophilia Therapeutics Market Key Players
• Biogen, Inc • Shire Plc • Baxter • Novo Nordisk A/S • Genentech, Inc • Ferring B.V • Pfizer, Inc • BioXcel Corporation • GlaxoSmithKline Plc • Mylan N.V • Sanofi SA • Teva Pharmaceuticals • F.Hoffman La Roche • Bristol-Myers Squibb Frequently Asked Questions: 1. Which region has the largest share in Global Acquired Haemophilia Therapeutics Market? Ans: North America region held the highest share in 2022. 2. What is the growth rate of Global Acquired Haemophilia Therapeutics Market? Ans: The Global Acquired Haemophilia Therapeutics Market is growing at a CAGR of 4.9% during forecasting period 2023-2029. 3. What is scope of the Global Acquired Haemophilia Therapeutics Market report? Ans: Global Acquired Haemophilia Therapeutics Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global Acquired Haemophilia Therapeutics Market? Ans: The important key players in the Global Acquired Haemophilia Therapeutics Market are – Biogen, Inc, Shire Plc, Baxter, Novo Nordisk A/S, Genentech, Inc, Ferring B.V, Pfizer, Inc, BioXcel Corporation, GlaxoSmithKline Plc, Mylan N.V, Sanofi SA, Teva Pharmaceuticals, F.Hoffman La Roche, Bristol-Myers Squibb 5. What is the study period of this Market? Ans: The Global Acquired Haemophilia Therapeutics Market is studied from 2022 to 2029.
Global Acquired Haemophilia Therapeutics Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: ACQUIRED HAEMOPHILIA THERAPEUTICS Market Size, By Market Value (US$ Mn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global ACQUIRED HAEMOPHILIA THERAPEUTICS Market Analysis and Forecast 6.1. ACQUIRED HAEMOPHILIA THERAPEUTICS Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global ACQUIRED HAEMOPHILIA THERAPEUTICS Market Analysis and Forecast, By Therapy type 7.1. Introduction and Definition 7.2. Key Findings 7.3. ACQUIRED HAEMOPHILIA THERAPEUTICS Market Value Share Analysis, By Therapy type 7.4. ACQUIRED HAEMOPHILIA THERAPEUTICS Market Size (US$ Mn) Forecast, By Therapy type 7.5. ACQUIRED HAEMOPHILIA THERAPEUTICS Market Analysis, By Therapy type 7.6. ACQUIRED HAEMOPHILIA THERAPEUTICS Market Attractiveness Analysis, By Therapy type 8. Global ACQUIRED HAEMOPHILIA THERAPEUTICS Market Analysis and Forecast, By Distribution Channels 8.1. Introduction and Definition 8.2. Key Findings 8.3. ACQUIRED HAEMOPHILIA THERAPEUTICS Market Value Share Analysis, By Distribution Channels 8.4. ACQUIRED HAEMOPHILIA THERAPEUTICS Market Size (US$ Mn) Forecast, By Distribution Channels 8.5. ACQUIRED HAEMOPHILIA THERAPEUTICS Market Analysis, By Distribution Channels 8.6. ACQUIRED HAEMOPHILIA THERAPEUTICS Market Attractiveness Analysis, By Distribution Channels 9. Global ACQUIRED HAEMOPHILIA THERAPEUTICS Market Analysis, By Region 9.1. ACQUIRED HAEMOPHILIA THERAPEUTICS Market Value Share Analysis, By Region 9.2. ACQUIRED HAEMOPHILIA THERAPEUTICS Market Size (US$ Mn) Forecast, By Region 9.3. ACQUIRED HAEMOPHILIA THERAPEUTICS Market Attractiveness Analysis, By Region 10. North America ACQUIRED HAEMOPHILIA THERAPEUTICS Market Analysis 10.1. Key Findings 10.2. North America ACQUIRED HAEMOPHILIA THERAPEUTICS Market Overview 10.3. North America ACQUIRED HAEMOPHILIA THERAPEUTICS Market Value Share Analysis, By Therapy type 10.4. North America ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Therapy type 10.4.1. Traditional Therapy 10.4.2. Advanced Therapy 10.5. North America ACQUIRED HAEMOPHILIA THERAPEUTICS Market Value Share Analysis, By Distribution Channels 10.6. North America ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Distribution Channels 10.6.1. Hospital Pharmacies 10.6.2. Retail Pharmacies 10.6.3. Online Pharmacies 10.7. North America ACQUIRED HAEMOPHILIA THERAPEUTICS Market Value Share Analysis, By Country 10.8. North America ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Country 10.8.1. U.S. 10.8.2. Canada 10.8.3. Mexico 10.9. North America ACQUIRED HAEMOPHILIA THERAPEUTICS Market Analysis, By Country 10.10. U.S. ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Therapy type 10.10.1. Traditional Therapy 10.10.2. Advanced Therapy 10.11. U.S. ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Distribution Channels 10.11.1. Hospital Pharmacies 10.11.2. Retail Pharmacies 10.11.3. Online Pharmacies 10.12. Canada ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Therapy type 10.12.1. Traditional Therapy 10.12.2. Advanced Therapy 10.13. Canada ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Distribution Channels 10.13.1. Hospital Pharmacies 10.13.2. Retail Pharmacies 10.13.3. Online Pharmacies 10.14. Mexico ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Therapy type 10.14.1. Traditional Therapy 10.14.2. Advanced Therapy 10.15. Mexico ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Distribution Channels 10.15.1. Hospital Pharmacies 10.15.2. Retail Pharmacies 10.15.3. Online Pharmacies 10.16. North America ACQUIRED HAEMOPHILIA THERAPEUTICS Market Attractiveness Analysis 10.16.1. By Therapy type 10.16.2. By Distribution Channels 10.17. PEST Analysis 10.18. Key Trends 10.19. Key Developments 11. Europe ACQUIRED HAEMOPHILIA THERAPEUTICS Market Analysis 11.1. Key Findings 11.2. Europe ACQUIRED HAEMOPHILIA THERAPEUTICS Market Overview 11.3. Europe ACQUIRED HAEMOPHILIA THERAPEUTICS Market Value Share Analysis, By Therapy type 11.4. Europe ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Therapy type 11.4.1. Traditional Therapy 11.4.2. Advanced Therapy 11.5. Europe ACQUIRED HAEMOPHILIA THERAPEUTICS Market Value Share Analysis, By Distribution Channels 11.6. Europe ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Distribution Channels 11.6.1. Hospital Pharmacies 11.6.2. Retail Pharmacies 11.6.3. Online Pharmacies 11.7. Europe ACQUIRED HAEMOPHILIA THERAPEUTICS Market Value Share Analysis, By Country 11.8. Europe ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Country 11.8.1. Germany 11.8.2. U.K. 11.8.3. France 11.8.4. Italy 11.8.5. Spain 11.8.6. Sweden 11.8.7. CIS countries 11.8.8. Rest of Europe 11.9. Germany ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Therapy type 11.9.1. Traditional Therapy 11.9.2. Advanced Therapy 11.10. Germany ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Distribution Channels 11.10.1. Hospital Pharmacies 11.10.2. Retail Pharmacies 11.10.3. Online Pharmacies 11.11. U.K. ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Therapy type 11.11.1. Traditional Therapy 11.11.2. Advanced Therapy 11.12. U.K. ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Distribution Channels 11.12.1. Hospital Pharmacies 11.12.2. Retail Pharmacies 11.12.3. Online Pharmacies 11.13. France ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Therapy type 11.13.1. Traditional Therapy 11.13.2. Advanced Therapy 11.14. France ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Distribution Channels 11.14.1. Hospital Pharmacies 11.14.2. Retail Pharmacies 11.14.3. Online Pharmacies 11.15. Italy ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Therapy type 11.15.1. Traditional Therapy 11.15.2. Advanced Therapy 11.16. Italy ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Distribution Channels 11.16.1. Hospital Pharmacies 11.16.2. Retail Pharmacies 11.16.3. Online Pharmacies 11.17. Spain ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Therapy type 11.17.1. Traditional Therapy 11.17.2. Advanced Therapy 11.18. Spain ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Distribution Channels 11.18.1. Hospital Pharmacies 11.18.2. Retail Pharmacies 11.18.3. Online Pharmacies 11.19. Sweden ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Therapy type 11.19.1. Traditional Therapy 11.19.2. Advanced Therapy 11.20. Sweden ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Distribution Channels 11.20.1. Hospital Pharmacies 11.20.2. Retail Pharmacies 11.20.3. Online Pharmacies 11.21. CIS countries ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Therapy type 11.21.1. Traditional Therapy 11.21.2. Advanced Therapy 11.22. CIS countries ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Distribution Channels 11.22.1. Hospital Pharmacies 11.22.2. Retail Pharmacies 11.22.3. Online Pharmacies 11.23. Rest of Europe ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Therapy type 11.23.1. Traditional Therapy 11.23.2. Advanced Therapy 11.24. Rest of Europe ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Distribution Channels 11.24.1. Hospital Pharmacies 11.24.2. Retail Pharmacies 11.24.3. Online Pharmacies 11.25. Europe ACQUIRED HAEMOPHILIA THERAPEUTICS Market Attractiveness Analysis 11.25.1. By Distribution Channels 11.25.2. By Therapy type 11.26. PEST Analysis 11.27. Key Trends 11.28. Key Developments 12. Asia Pacific ACQUIRED HAEMOPHILIA THERAPEUTICS Market Analysis 12.1. Key Findings 12.2. Asia Pacific ACQUIRED HAEMOPHILIA THERAPEUTICS Market Overview 12.3. Asia Pacific ACQUIRED HAEMOPHILIA THERAPEUTICS Market Value Share Analysis, By Therapy type 12.4. Asia Pacific ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Therapy type 12.4.1. Traditional Therapy 12.4.2. Advanced Therapy 12.5. Asia Pacific ACQUIRED HAEMOPHILIA THERAPEUTICS Market Value Share Analysis, By Distribution Channels 12.6. Asia Pacific ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Distribution Channels 12.6.1. Hospital Pharmacies 12.6.2. Retail Pharmacies 12.6.3. Online Pharmacies 12.7. Asia Pacific ACQUIRED HAEMOPHILIA THERAPEUTICS Market Value Share Analysis, By Country 12.8. Asia Pacific ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Country 12.8.1. China 12.8.2. India 12.8.3. Japan 12.8.4. South Korea 12.8.5. Australia 12.8.6. ASEAN 12.8.7. Rest of Asia Pacific 12.9. Asia Pacific ACQUIRED HAEMOPHILIA THERAPEUTICS Market Analysis, By Country 12.10. China ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Therapy type 12.10.1. Traditional Therapy 12.10.2. Advanced Therapy 12.11. China ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Distribution Channels 12.11.1. Hospital Pharmacies 12.11.2. Retail Pharmacies 12.11.3. Online Pharmacies 12.12. India ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Therapy type 12.12.1. Traditional Therapy 12.12.2. Advanced Therapy 12.13. India ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Distribution Channels 12.13.1. Hospital Pharmacies 12.13.2. Retail Pharmacies 12.13.3. Online Pharmacies 12.14. Japan ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Therapy type 12.14.1. Traditional Therapy 12.14.2. Advanced Therapy 12.15. Japan ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Distribution Channels 12.15.1. Hospital Pharmacies 12.15.2. Retail Pharmacies 12.15.3. Online Pharmacies 12.16. South Korea ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Therapy type 12.16.1. Traditional Therapy 12.16.2. Advanced Therapy 12.17. South Korea ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Distribution Channels 12.17.1. Hospital Pharmacies 12.17.2. Retail Pharmacies 12.17.3. Online Pharmacies 12.18. Australia ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Therapy type 12.18.1. Traditional Therapy 12.18.2. Advanced Therapy 12.19. Australia ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Distribution Channels 12.19.1. Hospital Pharmacies 12.19.2. Retail Pharmacies 12.19.3. Online Pharmacies 12.20. ASEAN ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Therapy type 12.20.1. Traditional Therapy 12.20.2. Advanced Therapy 12.21. ASEAN ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Distribution Channels 12.21.1. Hospital Pharmacies 12.21.2. Retail Pharmacies 12.21.3. Online Pharmacies 12.22. Rest of Asia Pacific ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Therapy type 12.22.1. Traditional Therapy 12.22.2. Advanced Therapy 12.23. Rest of Asia Pacific ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Distribution Channels 12.23.1. Hospital Pharmacies 12.23.2. Retail Pharmacies 12.23.3. Online Pharmacies 12.24. Asia Pacific ACQUIRED HAEMOPHILIA THERAPEUTICS Market Attractiveness Analysis 12.24.1. By Therapy type 12.24.2. By Distribution Channels 12.25. PEST Analysis 12.26. Key Trends 12.27. Key Developments 13. Middle East & Africa ACQUIRED HAEMOPHILIA THERAPEUTICS Market Analysis 13.1. Key Findings 13.2. Middle East & Africa ACQUIRED HAEMOPHILIA THERAPEUTICS Market Overview 13.3. Middle East & Africa ACQUIRED HAEMOPHILIA THERAPEUTICS Market Value Share Analysis, By Therapy type 13.4. Middle East & Africa ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Therapy type 13.4.1. Traditional Therapy 13.4.2. Advanced Therapy 13.5. Middle East & Africa ACQUIRED HAEMOPHILIA THERAPEUTICS Market Value Share Analysis, By Distribution Channels 13.6. Middle East & Africa ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Distribution Channels 13.6.1. Hospital Pharmacies 13.6.2. Retail Pharmacies 13.6.3. Online Pharmacies 13.7. Middle East & Africa ACQUIRED HAEMOPHILIA THERAPEUTICS Market Value Share Analysis, By Country 13.8. Middle East & Africa ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Country 13.8.1. GCC Countries 13.8.2. South Africa 13.8.3. Nigeria 13.8.4. Egypt 13.8.5. Rest of Middle East & Africa 13.9. Middle East & Africa ACQUIRED HAEMOPHILIA THERAPEUTICS Market Analysis, By Country 13.10. GCC Countries ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Therapy type 13.10.1. Traditional Therapy 13.10.2. Advanced Therapy 13.11. GCC Countries ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Distribution Channels 13.11.1. Hospital Pharmacies 13.11.2. Retail Pharmacies 13.11.3. Online Pharmacies 13.12. South Africa ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Therapy type 13.12.1. Traditional Therapy 13.12.2. Advanced Therapy 13.13. South Africa ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Distribution Channels 13.13.1. Hospital Pharmacies 13.13.2. Retail Pharmacies 13.13.3. Online Pharmacies 13.14. Nigeria ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Therapy type 13.14.1. Traditional Therapy 13.14.2. Advanced Therapy 13.15. Nigeria ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Distribution Channels 13.15.1. Hospital Pharmacies 13.15.2. Retail Pharmacies 13.15.3. Online Pharmacies 13.16. Egypt ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Therapy type 13.16.1. Traditional Therapy 13.16.2. Advanced Therapy 13.17. Egypt ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Distribution Channels 13.17.1. Hospital Pharmacies 13.17.2. Retail Pharmacies 13.17.3. Online Pharmacies 13.18. Rest of Middle East & Africa ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Therapy type 13.18.1. Traditional Therapy 13.18.2. Advanced Therapy 13.19. Rest of Middle East & Africa ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Distribution Channels 13.19.1. Hospital Pharmacies 13.19.2. Retail Pharmacies 13.19.3. Online Pharmacies 13.20. Middle East & Africa ACQUIRED HAEMOPHILIA THERAPEUTICS Market Attractiveness Analysis 13.20.1. By Therapy type 13.20.2. By Distribution Channels 13.21. PEST Analysis 13.22. Key Trends 13.23. Key Developments 14. South America ACQUIRED HAEMOPHILIA THERAPEUTICS Market Analysis 14.1. Key Findings 14.2. South America ACQUIRED HAEMOPHILIA THERAPEUTICS Market Overview 14.3. South America ACQUIRED HAEMOPHILIA THERAPEUTICS Market Value Share Analysis, By Therapy type 14.4. South America ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Therapy type 14.4.1. Traditional Therapy 14.4.2. Advanced Therapy 14.5. South America ACQUIRED HAEMOPHILIA THERAPEUTICS Market Value Share Analysis, By Distribution Channels 14.6. South America ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Distribution Channels 14.6.1. Hospital Pharmacies 14.6.2. Retail Pharmacies 14.6.3. Online Pharmacies 14.7. South America ACQUIRED HAEMOPHILIA THERAPEUTICS Market Value Share Analysis, By Country 14.8. South America ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Country 14.8.1. Brazil 14.8.2. Colombia 14.8.3. Argentina 14.8.4. Rest of South America 14.9. South America ACQUIRED HAEMOPHILIA THERAPEUTICS Market Analysis, By Country 14.10. Brazil ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Therapy type 14.10.1. Traditional Therapy 14.10.2. Advanced Therapy 14.11. Brazil ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Distribution Channels 14.11.1. Hospital Pharmacies 14.11.2. Retail Pharmacies 14.11.3. Online Pharmacies 14.12. Colombia ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Therapy type 14.12.1. Traditional Therapy 14.12.2. Advanced Therapy 14.13. Colombia ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Distribution Channels 14.13.1. Hospital Pharmacies 14.13.2. Retail Pharmacies 14.13.3. Online Pharmacies 14.14. Argentina ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Therapy type 14.14.1. Traditional Therapy 14.14.2. Advanced Therapy 14.15. Argentina ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Distribution Channels 14.15.1. Hospital Pharmacies 14.15.2. Retail Pharmacies 14.15.3. Online Pharmacies 14.16. Rest of South America ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Therapy type 14.16.1. Traditional Therapy 14.16.2. Advanced Therapy 14.17. Rest of South America ACQUIRED HAEMOPHILIA THERAPEUTICS Market Forecast, By Distribution Channels 14.17.1. Hospital Pharmacies 14.17.2. Retail Pharmacies 14.17.3. Online Pharmacies 14.18. South America ACQUIRED HAEMOPHILIA THERAPEUTICS Market Attractiveness Analysis 14.18.1. By Therapy type 14.18.2. By Distribution Channels 14.19. PEST Analysis 14.20. Key Trends 14.21. Key Developments 15. Company Profiles 15.1. Market Share Analysis, By Company 15.2. Competition Matrix 15.2.1. Competitive Benchmarking of key players By price, presence, market share, Distribution Channels, and R&D investment 15.2.2. New Product Launches and Product Enhancements 15.2.3. Market Consolidation 15.2.3.1. M&A By Regions, Investment and Distribution Channels 15.2.3.2. M&A Key Players, Forward Integration and Backward Integration 15.3. Company Profiles: Key Players 15.3.1. Biogen, Inc 15.3.1.1. Company Overview 15.3.1.2. Financial Overview 15.3.1.3. Product Portfolio 15.3.1.4. Business Strategy 15.3.1.5. Recent Developments 15.3.1.6. Development Footprint 15.3.2. Shire Plc 15.3.3. Baxter 15.3.4. Novo Nordisk A/S 15.3.5. Genentech, Inc 15.3.6. Ferring B.V 15.3.7. Pfizer, Inc 15.3.8. BioXcel Corporation 15.3.9. GlaxoSmithKline Plc 15.3.10. Mylan N.V 15.3.11. Sanofi SA 15.3.12. Teva Pharmaceuticals 15.3.13. F.Hoffman La Roche 15.3.14. Bristol-Myers Squibb